Evaluates the potential of targeting nectin-4 to improve outcomes in pancreatic cancer, suggesting a novel treatment avenue.
Nectin-4 is an immunoglobulinlike cell adhesion molecule that contributes to tumor aggressiveness and immune evasion in pancreatic ductal adenocarcinoma (PDAC). Its high and selective expression on pancreatic cancer cells, together with the clinical efficacy of nectin-4-targeted antibody-drug conjugates in other solid tumors, establishes nectin-4 as a compelling therapeutic target in PDAC.
No takes yet. Share an insight, caveat, or question.
Cronjaeger et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Trends in cancer